Sir, Widespread use of vancomycin has led to the emergence of isolates that show reduced susceptibility to vancomycin; vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-resistant S. aureus (VRSA) and heteroresistant VISA (hVISA) have been described. 1 The emergence of such strains with concomitant vancomycin therapeutic failures 2 has necessitated the development of other therapeutic agents.
Newer drugs of the glycopeptide class, such as oritavancin, with activity against isolates with reduced susceptibility to vancomycin are currently in development. Additional mechanisms exhibited by oritavancin help explain its rapid, concentration-dependent bactericidal activity in vitro 3 and distinguish it from vancomycin. In surveillance studies, oritavancin activity was demonstrated against vancomycin-susceptible S. aureus isolates that are susceptible and resistant to methicillin. 4 This study examined the in vitro activity of oritavancin against clinical isolates of VRSA, VISA and hVISA using recently updated broth microdilution methodology.
5 MICs and MBCs of oritavancin were determined for these groups of organisms and compared with those of seven clinically used antimicrobial agents.
MICs of antimicrobial agents were determined by broth microdilution according to CLSI (formerly NCCLS) guidelines.
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Polysorbate-80 was included when testing oritavancin, so as to limit losses of oritavancin to the surfaces of test vessels as recommended in CLSI guidelines.
MBCs were also determined according to CLSI guidelines. 6 Aliquots (50 mL) were plated onto brain heart infusion agar (BHIA) plates for the VISA and hVISA isolates, or BHIA plates containing 4 mg/L vancomycin for the VRSA isolates to maintain selection for vancomycin, and incubated at 358C for 24 h. The MBC was defined as the lowest concentration killing .99.9% of the original inoculum. 6 Oritavancin showed good in vitro activity against the hVISA isolates (MIC range of 0.12 -2 mg/L and MIC 90 of 1 mg/L; Table 1 ). The oritavancin MIC 90 was identical to those of linezolid and quinupristin/dalfopristin, and one doubling dilution higher than that of tigecycline. The oritavancin MIC 90 was 2-to 8-fold lower than those of the rest of the comparators. The oritavancin MBC range and MBC 90 against hVISAs were 0.25 -2 and 1 mg/L, respectively. The oritavancin MBC 90 against the hVISA isolates was identical to that of tigecycline and 2-to 64-fold lower than those of the rest of the comparators. The oritavancin MBC 90 /MIC 90 ratio of 1 indicates that oritavancin is bactericidal against hVISA. The oritavancin MBC 90 /MIC 90 ratio was identical to that of daptomycin and 2-to 16-fold lower than those of the rest of the comparators.
Oritavancin showed good in vitro activity against the VISA isolates (MIC range of 0.5 -4 mg/L and MIC 90 of 2 mg/L; Table 1 ). The MIC 90 was identical to that of quinupristin/dalfopristin and was two doubling dilutions higher than that of tigecycline. The oritavancin MIC 90 was 2-to 8-fold lower than those of the rest of the comparators. The oritavancin MBC range and MBC 90 against VISAs were 0.5 -8 and 4 mg/L, respectively. The oritavancin MBC 90 for the VISA isolates was 4-fold higher than that of tigecycline and 2-to 8-fold lower than those of the rest of the comparators. The oritavancin MBC 90 /MIC 90 ratio of 2 indicates that oritavancin is bactericidal against VISA. The oritavancin MBC 90 /MIC 90 ratio was identical to, or within a dilution of, those of the comparators.
Oritavancin showed good in vitro activity against the VRSA isolates (MIC range of 0.12 -1 mg/L and MIC 90 of 0.5 mg/L; Table 1 ). The MIC 90 was identical to that of daptomycin and was a doubling dilution higher than that of tigecycline. The oritavancin MIC 90 was 2-to .1024-fold lower than those of the rest of the comparators. The oritavancin MBC range and MBC 90 against VRSAs were 0.25-1 and 1 mg/L, respectively. The oritavancin MBC 90 for the VRSA isolates was 2-to .512-fold lower than those of the comparators. The oritavancin MBC 90 /MIC 90 ratio of 2 indicates that oritavancin is bactericidal against VRSA. The oritavancin MBC 90 /MIC 90 ratio was at least 2-fold lower than those of the comparators.
Against the 35 isolates of S. aureus tested in this study, the oritavancin MIC range and MIC 90 were 0.12-4 and 1 mg/L, respectively ( Table 1 ). The oritavancin MIC 90 was identical to that of quinupristin/dalfopristin and was a doubling dilution higher than that of tigecycline. The oritavancin MIC 90 was !2-fold lower than those of the rest of the comparators. The oritavancin MBC range and MBC 90 were 0.25 -8 and 4 mg/L, respectively. The oritavancin MBC 90 against the 35 isolates was 2-fold higher than that of tigecycline. Oritavancin MBC 90 was at least 2-fold lower than those of the other comparators ( Table 1) .
The in vitro data in this study suggest that oritavancin could be an attractive candidate in the treatment of infections caused by S. aureus strains that have challenges with vancomycin therapy.
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All authors were full-time employees of Targanta Therapeutics Inc., Ville Saint Laurent, Canada at the time this work was performed and had no significant declarations to make with respect to external funding, ownership of company stocks or shares and reimbursement for preparing this article. Targanta Therapeutics is now a fully owned subsidiary of The Medicines Company. Sir, Many relatively solvent-tolerant bacteria, notably species of Pseudomonas, are capable of extruding organic solvent via energy-dependent efflux systems, thus reducing their intracellular concentration below toxic levels. 1,2 Some reports suggest that organic solvent tolerance (OST) and antibacterial resistance are positively correlated since the widely studied multisubstrate AcrAB efflux pump can extrude many unrelated antibacterials as well as organic solvents. 1 -5 It has been hypothesized, therefore, that OST might be an indicator of efflux pump activity associated with resistance to fluoroquinolones and other antimicrobials.
2 However, while Schneiders et al. 6 found that 10 of 19 fluoroquinolone-resistant clinical isolates of Klebsiella pneumoniae were tolerant to cyclohexane, they found no correlation between OST and fluoroquinolone MICs.
In order to test the hypothesis that OST can predict fluoroquinolone resistance and possibly efflux pump activity, the present study investigated the association between OST and ciprofloxacin susceptibility amongst 75 distinct clinical isolates of K. pneumoniae with varying ciprofloxacin MICs, and a K. pneumoniae reference strain. The MICs of ciprofloxacin for these 76 strains were determined by the agar dilution method described by the BSAC guidelines.
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The isolates were tested for OST using a modification of the method of White et al. 4 with the organic solvents hexane, cyclohexane and their mixtures. Isolates were cultured to midlogarithmic phase in Luria -Bertani (LB) broth, spotted on to LB agar, allowed to dry, overlaid with 2 -3 mm of organic solvent/mixture and incubated for 72 h at 218C in a fume cabinet. A confluent bacterial growth within a spot was considered OST positive and no growth OST negative. OST was tested at five arbitrary levels of toxicity (see Figure 1) . Growth in hexane alone (the least toxic) 4 was given a score of 1, and growth in increasingly toxic solvents/mixtures of 75% hexane/ 25% cyclohexane, 50% hexane/50% cyclohexane, 25% hexane/ 75% cyclohexane and 100% cyclohexane was given scores of 2, 3, 4 and 5, respectively. All experiments were performed in duplicate and gave the same results.
The association between OST and ciprofloxacin MICs was determined by using Pearson's correlation coefficient analysis.
The 75 K. pneumoniae clinical isolates and the reference strain had ciprofloxacin MICs ranging from 0.06 to .512 mg/L and included 10 -25 isolates within each of the ciprofloxacinsusceptible, reduced susceptible, moderately resistant and highly resistant groups. The relatively large number of isolates with a wide range of ciprofloxacin susceptibilities provided a better assessment of the association between ciprofloxacin MICs and OST than was possible with the study of Schneiders et al., 
